Antibiotic-nanomedicines: Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections

Jeffrey A.S. Ritsema, Hessel Van Der Weide, Yvonne M. Te Welscher, Wil H.F. Goessens, Cornelus F. Van Nostrum, Gert Storm, Irma A.J.M. Bakker-Woudenberg, John P. Hays (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.

Original languageEnglish
Pages (from-to)1683-1692
Number of pages10
JournalFuture microbiology
Volume13
Issue number15
DOIs
Publication statusPublished - 1 Nov 2018
Externally publishedYes

Fingerprint

Nanomedicine
Respiratory Tract Infections
Anti-Bacterial Agents
Therapeutics
Amikacin
Liposomes
Inhalation
Adsorption
Suspensions
Infection

Keywords

  • aerosols
  • antibiotic nanomedicines
  • antibiotic resistance
  • pulmonary administration
  • respiratory tract infections

Cite this

Ritsema, J. A. S., Van Der Weide, H., Te Welscher, Y. M., Goessens, W. H. F., Van Nostrum, C. F., Storm, G., ... Hays, J. P. (2018). Antibiotic-nanomedicines: Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. Future microbiology, 13(15), 1683-1692. https://doi.org/10.2217/fmb-2018-0194
Ritsema, Jeffrey A.S. ; Van Der Weide, Hessel ; Te Welscher, Yvonne M. ; Goessens, Wil H.F. ; Van Nostrum, Cornelus F. ; Storm, Gert ; Bakker-Woudenberg, Irma A.J.M. ; Hays, John P. / Antibiotic-nanomedicines : Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. In: Future microbiology. 2018 ; Vol. 13, No. 15. pp. 1683-1692.
@article{c6056afe90224ddcb2aaf453ad029262,
title = "Antibiotic-nanomedicines: Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections",
abstract = "Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.",
keywords = "aerosols, antibiotic nanomedicines, antibiotic resistance, pulmonary administration, respiratory tract infections",
author = "Ritsema, {Jeffrey A.S.} and {Van Der Weide}, Hessel and {Te Welscher}, {Yvonne M.} and Goessens, {Wil H.F.} and {Van Nostrum}, {Cornelus F.} and Gert Storm and Bakker-Woudenberg, {Irma A.J.M.} and Hays, {John P.}",
year = "2018",
month = "11",
day = "1",
doi = "10.2217/fmb-2018-0194",
language = "English",
volume = "13",
pages = "1683--1692",
journal = "Future microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "15",

}

Ritsema, JAS, Van Der Weide, H, Te Welscher, YM, Goessens, WHF, Van Nostrum, CF, Storm, G, Bakker-Woudenberg, IAJM & Hays, JP 2018, 'Antibiotic-nanomedicines: Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections' Future microbiology, vol. 13, no. 15, pp. 1683-1692. https://doi.org/10.2217/fmb-2018-0194

Antibiotic-nanomedicines : Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. / Ritsema, Jeffrey A.S.; Van Der Weide, Hessel; Te Welscher, Yvonne M.; Goessens, Wil H.F.; Van Nostrum, Cornelus F.; Storm, Gert; Bakker-Woudenberg, Irma A.J.M.; Hays, John P. (Corresponding Author).

In: Future microbiology, Vol. 13, No. 15, 01.11.2018, p. 1683-1692.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Antibiotic-nanomedicines

T2 - Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections

AU - Ritsema, Jeffrey A.S.

AU - Van Der Weide, Hessel

AU - Te Welscher, Yvonne M.

AU - Goessens, Wil H.F.

AU - Van Nostrum, Cornelus F.

AU - Storm, Gert

AU - Bakker-Woudenberg, Irma A.J.M.

AU - Hays, John P.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.

AB - Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.

KW - aerosols

KW - antibiotic nanomedicines

KW - antibiotic resistance

KW - pulmonary administration

KW - respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=85058010048&partnerID=8YFLogxK

U2 - 10.2217/fmb-2018-0194

DO - 10.2217/fmb-2018-0194

M3 - Article

VL - 13

SP - 1683

EP - 1692

JO - Future microbiology

JF - Future microbiology

SN - 1746-0913

IS - 15

ER -